Document:

EX-10.1

 Exhibit 10.1 
  

					
			May 7, 2015		
			
			Edward J. Lehner		
			  
		
			  
		

  

			
			Dear Eddie:
			  
 Further to your discussion with the Board of Directors of Ryerson
Holding Corporation (the “Company” or “Ryerson”), this letter will confirm the general terms and conditions of your appointment to the position of President and Chief Executive Officer of the Company.

 
 Upon your acceptance, the effective date of your appointment shall be June 1, 2015
(“Effective Date”) and is contingent on the execution prior to the Effective Date by you of the Company’s standard Confidentiality, Non-Competition and Non-Solicitation Agreement, with such adjustments as are mutually agreed by the
Company and you (the “Non-Competition Agreement”).
  

COMPENSATION
  

Your base annual salary will be $650,000, to be paid in accordance with the Company’s regular payroll process and procedures during your employment and
will be subject to all applicable withholdings. Additionally, your target incentive percentage for the Company’s Annual Incentive Plan (“AIP”) shall be 110%, commencing with the Effective Date. Any 2015 plan year payout will be
prorated for the time you were employed in each of your positions during 2015.
  
 In
conjunction with the granting of equity-based long-term incentive awards to Company executives during 2015 (the “2015 LTI Grants”) under the 2014 Ryerson Holding Corporation Omnibus Incentive Plan, you will receive a grant of performance
units (“PSUs”) and time-vesting restricted stock units (“RSU”) in amounts such that the total number of RSUs and PSUs granted to you will equal 90,000. The terms and vesting rules for the RSUs and PSUs granted to you will be in
accordance with the terms established by the Company’s Board of Directors in connection with the 2015 LTI Grants.
  

VACATION
  

You will continue to be entitled to four (4) weeks of paid vacation annually.

			
			Mr. Edward Lehner
			 Page
 2

			May 7, 2015

  

			
			 BENEFITS
  

You and your qualified dependents will continue to be eligible for the benefit programs generally available to the Company’s office employees, including
medical, dental and vision and life insurance; short-term and long-term disability benefits, voluntary life and accidental death and dismemberment insurance, and the Company’s 401(k) plan.

 
 TEMPORARY LIVING

 
 It is also confirmed that the Company will continue to provide you with
support to cover your temporary living expenses in Chicago through August 31, 2016. These expenses will include the rent, utilities and upkeep of a studio apartment in the Loop area of Chicago and weekly transportation costs between Cleveland
and Chicago, and will include tax gross-up to cover any personal income taxes associated with these covered expenses. All other expenses will be a cost to you.
  

RELOCATION ASSISTANCE
  

It is anticipated that at some time prior to the 31st August 2016 you will relocate your family to
the Chicago area. The Company will provide support broadly in line with that outlined in the Company’s relocation policy. The precise terms will be discussed and agreed between you and the Company’s Board of Directors closer to the
event.
  
 AT-WILL EMPLOYMENT

 
 Your employment with the Company is at-will, and either you or the Company
may terminate your employment at any time, with or without cause. We ask that you provide at least 30 days’ notice if you wish to terminate your employment.
  

SEVERANCE
  

In the event that the Company terminates your employment without cause, then the Company shall pay you an amount equal to eighteen (18) months of your
then current base salary, which payment shall be subject to and reduced by all necessary and appropriate statutory payroll and benefit-related withholdings and deductions (the “Severance Payment”). The details and conditions relating to
the Severance Payment will be more fully set forth in the Non-Competition Agreement, and for the avoidance of doubt, any Severance Payment will be contingent on (i) your conformance with the provisions of the Non-Competition Agreement, and
(ii) your execution of a mutually acceptable release of the Company and its affiliates.

			
			Mr. Edward Lehner
			 Page
 3

			May 7, 2015

  

					
			 GENERAL
  

You agree that the provisions of this letter are severable; and if any portion thereof shall be declared unenforceable, the same shall not affect the
enforceability of all other provisions hereof. It is the intent of the parties to this letter that if any portion of this letter contains provisions which are held to be unreasonable then, in such event, a court shall fix the terms of this agreement
or shall enforce the terms and provisions hereof to the extent deemed reasonable by the court.
  

This letter, in conjunction with the Non-Competition Agreement, constitutes the sole and complete agreement between the Company and you and supersedes all
other agreements, both oral and written, between the Company or any of its direct and indirect subsidiaries and you with respect to your employment by the Company or any of its direct and indirect subsidiaries or the matters contained herein.

 
 This letter and the terms and conditions hereof are to be construed, governed and
interpreted in accordance with the laws of the State of Illinois, without giving effect to its conflict of law principles.
  

*****
  

Should you have any questions about this letter, please contact Roger Lindsay at 905-454-6801. Two copies of this letter are enclosed. Please sign both copies
and return one to me.

			
			Very Truly Yours,		
			
			/s/ Roger W. Lindsay		
			
			Roger W. Lindsay		
			Chief Human Resources Officer		

  

							
			AGREED TO AND ACCEPTED:		
				
			By:		 /s/ Edward J. Lehner
		
				
			Date:		 May 7, 2015Exhibit 10.1

 

AGREEMENT

 

This
Agreement (this “Agreement”), dated as of May 7, 2015, and effective April 15, 2015 (the “Effective
Date”), is made by and between Actinium Pharmaceuticals, Inc. (the “Company”) and Kaushik J. Dave
(the “Employee”).

  

WHEREAS,
the Company believes that it is in best interest to make certain payments, cancel certain restricted stock previously granted
to Employee, and make a new option grant to Employee pursuant to the terms and provisions of this Agreement.

 

NOW,
THEREFORE, in consideration of the premises and the mutual covenants set forth herein the parties hereby agree as follows:

 

1.Payments.
The Company hereby agrees to pay to Employee (i) $166,825 on or before the effective date; (ii) $22,021 on or before the effective date; (iii) $22,021 by June 30, 2015; (iv) $22,021 by September 30, 2015; (v) $22,021 by December 31, 2015; (vi) $46,490 by
April 15, 2016 so long as the Employee is an employee of the Company on such date; and (vii) $52,103 by December 31, 2016, so
long as the Employee is an employee of the Company on such date; provided however, that if Employee is not
employed by the Company (A) on April 15, 2016 then Employee shall repay to the Company $88,084 (which represents the payments
made on April 15, 2015, June 30, 2015, September 30, 2015 and December 31, 2015, of $20,021 each), and (B) on December 31,
2016 then Employee shall repay to the Company $46,490 (which represents the payment made on April 15, 2016).

 

2.Lockup.
Until December 31, 2016, the Employee will not, without the prior written consent of the Company, directly or indirectly, offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
right or warrant for the sale of, or otherwise dispose of or transfer 25,000 shares of common stock of the Company, which such
shares vested on September 16, 2014.

 

3.Restricted
Stock Grant. The Employee and the Company each agree that the 68,000 shares of restricted stock previously granted to Employee
on February 21, 2014, and are unvested, shall be cancelled and that the Company shall grant to Employee 82,128 options which shall
vest according to the following schedule:

 

	No.
    of Shares of common stock underlying options	 	Date
    of

Grant	 	Vesting
	82,128

         

        10
        year term

         

        $2.52
        exercise price

         

        Subject
        to terms and provisions of the company’s 2014 Stock Plan
	 	May
    7, 2015	 	Achievement
of certain milestones: 

         

        ●      Filing
        IND‎ (50%)

        ●      First
Patient in (10%) 

        ●      Hiring
of VP-Mfg or other competent person and training so that person is capable of producing Iomab-B (25%) 

        ●      Completion
of Actimab-A 1 step labeling (10%) 

        ●      VP
        Manufacturing or other competent person to handle manufacturing and logistics of Actimab-A (5%)

 

    	-1-

    	 

    

 

4.Miscellaneous.

 

(a)Entire
Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties with respect
to the subject matter hereof and supersede all other prior agreements and understandings, both written and oral, between the parties
with respect to such subject matter.

 

(b)Assignment.
This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted
assigns. This Agreement is not intended to confer upon any person or entity other than the parties hereto any rights or remedies
hereunder, except as otherwise expressly provided herein. This Agreement shall not be assignable except that the Company may assign
this contract in connection with a merger, consolidation or sale of all or substantially all of its assets or that portion of
its business to which this Agreement relates.

 

(c)Amendments
and Supplements. This Agreement may not be altered, changed or amended, except by an instrument in writing signed by the parties
hereto.

 

(d)No
Waiver. The terms and conditions of this Agreement may be waived only by a written instrument signed by the party waiving
compliance. The failure of any party hereto to enforce at any time any of the provisions of this Agreement shall in no way be
construed to be a waiver of any such provision, nor in any way to affect the validity of this Agreement or any part hereof or
the right of such party thereafter to enforce each and every such provision. No waiver of any breach of or non-compliance with
this Agreement shall be held to be a waiver of any other or subsequent breach or non-compliance.

 

(e)Governing
Law; Jurisdiction. This Agreement shall be governed by, and construed and enforced in accordance with, the substantive laws
of the State of New York, without regard to its principles of conflicts of laws. Each party consents to the jurisdiction and venue
of the state and federal courts, as applicable, located in the New York metropolitan area.

 

(f)Counterparts.
This Agreement may be executed in one or more counterparts, all of which together shall constitute one and the same Agreement.
Facsimile transmission of executed copies or signature pages for this Agreement shall be legal, valid and binding execution and
delivery for all purposes.

 

*   *   *

 

    	-2-

    	 

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed as an agreement under seal as of the date first written
above.

 

	 	ACTINIUM
    PHARMACEUTICALS, INC.
	 	 	 
	 	By:	/s/
    David Nicholson
	 	Name:	David
    Nicholson
	 	Title:	Chairman
    Compensation Committee
	 	 	 
	 	EMPLOYEE:
	 	 	 
	 	/s/
    Kaushik J. Dave
	 	Name:	Kaushik
    J. Dave

 

 

-3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}]]